8-K: Incannex Healthcare Completes Patient Dosing in Phase 2 OSA Study, Topline Results Expected in July

Incannex Healthcare Inc. announces the completion of patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study evaluating IHL-42X for obstructive sleep apnea (OSA), with topline results anticipated in July 2025.

Summary

• Incannex Healthcare Inc. has completed patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study of IHL-42X for obstructive sleep apnea (OSA).
• End-of-study follow-up assessments are on track for completion by May 17, 2025.
• Topline results from the Phase 2 study are expected in July 2025.
• The company is preparing for an end-of-Phase 2 meeting with the FDA to discuss results and next steps toward a 505(b)(2) NDA submission.
• Phase 3 planning is underway and will be conducted exclusively at U.S. sites, recruiting 440 patients.
• IHL-42X is designed to target two key physiological pathways, intermittent hypoxia (IH) and hypercapnia, that underlie the pathology of OSA.
• In a prior Australian Phase 2 clinical trial, IHL-42X demonstrated clinically meaningful reductions in the Apnea-Hypopnea Index (AHI), with the lowest dose reducing AHI by an average of 51% from baseline.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the completion of patient dosing in Phase 2 and the anticipation of topline results. The company expresses confidence in the IHL-42X program and its potential to address a significant unmet need in the OSA treatment market. However, forward-looking statements are subject to risks and uncertainties.

Positives

• Patient dosing in Phase 2 was completed rapidly.
• The IHL-42X program has strong momentum.
• The company is well-positioned to advance IHL-42X as a potential first-in-class oral treatment for OSA.
• There is enthusiasm from U.S. clinical sites and trial participants.
• IHL-42X is uniquely engineered to target two key physiological pathways, intermittent hypoxia (IH) and hypercapnia.
• In a prior Australian Phase 2 clinical trial, IHL-42X demonstrated clinically meaningful reductions in the Apnea-Hypopnea Index (AHI), with the lowest dose reducing AHI by an average of 51% from baseline.
• The company has engaged in several promising commercial discussions regarding IHL-42X.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the continued availability of financing and the success of Incannex's development efforts.
• Competition from other providers and products could impact the success of IHL-42X.
• Incannex's compliance with evolving laws and regulations is a risk factor.
• The company's ability to protect its proprietary technology and intellectual property is a risk.

Future Outlook

The company anticipates topline data from the Phase 2 portion of the RePOSA study in July 2025 and is preparing for an end-of-Phase 2 meeting with the FDA to discuss results and next steps toward a 505(b)(2) NDA submission. Phase 3 planning is underway and will be conducted exclusively at U.S. sites.

Management Comments

• We are pleased with the rapid completion of patient dosing in the Phase 2 study, said Joel Latham, President and CEO of Incannex.
• The IHL-42X program continues its strong momentum as we prepare for data analysis and advance toward our end-of-Phase 2 meeting with the FDA.
• The third quarter of 2025 represents a pivotal period of progress for the company.
• With the successful completion of Phase 2 enrollment, encouraging pharmacokinetic and safety data, and expanded clinical advisory expertise, we are well-positioned to advance IHL-42X as a potential first-in-class oral treatment for millions of patients living with OSA.

Industry Context

The announcement highlights Incannex's efforts to address the significant unmet need in the OSA treatment market, which is currently dominated by mechanical interventions like CPAP devices. IHL-42X is positioned as a potential breakthrough oral treatment, targeting the underlying pathophysiology of OSA.

Comparison to Industry Standards

• The document mentions that IHL-42X is uniquely positioned to address one of the most prevalent sleep disorders worldwide.
• The company believes IHL-42X will offer a significant breakthrough in a therapeutic area long dominated by mechanical interventions like CPAP devices.
• Unlike weight loss therapies, IHL-42X is uniquely engineered to target two key physiological pathways, intermittent hypoxia (IH) and hypercapnia, that underlie the pathology of OSA.
• This differentiated mechanism positions IHL-42X as a potential treatment option for a broader OSA population, including the 67% of patients who are not obese.
• In a previously completed Phase 2 clinical trial conducted in Australia, IHL-42X demonstrated clinically meaningful reductions in the Apnea-Hypopnea Index (AHI) across all dose levels, with the lowest dose reducing AHI by an average of 51% from baseline.

Stakeholder Impact

• Shareholders may benefit from the potential success of IHL-42X and its commercialization.
• Patients with OSA may have a new treatment option if IHL-42X is approved.
• The company's employees are involved in the clinical development and commercialization efforts.

Next Steps

• Completion of end-of-study follow-up assessments by May 17, 2025.
• Topline data readout expected in July 2025.
• End-of-Phase 2 meeting with the FDA.
• Phase 3 planning and initiation at U.S. sites.

Key Dates

Keywords

IHL-42X, Obstructive Sleep Apnea, OSA, Incannex Healthcare, Clinical Trial, Phase 2/3, RePOSA, Dronabinol, Acetazolamide, Apnea-Hypopnea Index, AHI, FDA, Clinical Program